ClinicalTrials.gg
Not yet recruitingNCT07423520HI-FIVEUpdated Feb 20, 2026

HemodynamIc eFfects of Lung Collapse and overdIstension During ARDS

An interventional study of Change in PEEP in ARDS and AHRF, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The management ARDS relies on ventilatory strategies aimed at limiting ventilator-induced lung injury (VILI). The setting of PEEP is still subject of debate, as randomized clinical trials comparing standardized higher versus lower PEEP strategies failed to demonstrate a clear survival advantage. Only few studies explored the hemodynamic effects of various PEEP levels depending on lung recruitability. Furthermore, the role of PEEP-mediated lung collapse and overdistention on patients' hemodynamics has yet to be elucidated. In this physiologic study, the association between EIT-measured lung collapse and overdistention and cardiac function will be explored, accounting for the individual potential for lung recruitment, partitioned respiratory mechanics and cardiac preload responsiveness. Three PEEP levels will be tested in a randomized, crossover fashion: PEEP corresponding to the crossing point between lung collapse and overdistention, PEEP associated with low lung collapse, PEEP associated with low lung overdistention.

02

Conditions studied

  • ARDS
  • AHRF

Keywords

  • ARDS
  • AHRF
  • acute respiratory distress syndrome
  • PEEP
  • collapse
  • overdistention
  • hemodynamics
  • heart-lung interactions
  • mechanical ventilation
  • randomized crossover trial
03

In context

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 283 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute respiratory failure with onset \< 1 week from a predisposing risk factor, such as pneumonia, non-pulmonary infection, trauma, transfusion, aspiration, or shock;
  • bilateral opacities on chest radiography and computed tomography or bilateral B lines and/or consolidations on lung ultrasound not fully explained by effusions, atelectasis, or nodules/masses;
  • pulmonary edema not exclusively or primarily attributable to cardiogenic pulmonary edema/fluid overload, and hypoxemia/gas exchange abnormalities not primarily attributable to atelectasis;
  • PaO2/FiO2 ratio ≤ 200 during invasive controlled mechanical ventilation;

Exclusion criteria

Exclusion Criteria:

  • age \<18 years;
  • pregnancy;
  • signs of barotrauma or documented pneumothorax;
  • severe tachycardia (HR > 120 bpm) and severe lacticaemia (lac > 4 mmol/L)
  • pre-existing decompensated heart failure ( class 3-4 and/or documented \< 35%);
  • to EIT placing (open chest wounds, presence of cardiac pacemaker);
  • intubation as a result of an acute exacerbation of chronic pulmonary disease;
  • contraindications to esophageal balloon placement (high bleeding risk, esophageal varices).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Lung collapse and overdistention crossing point PEEP

    Other: Change in PEEP

  • Experimental
    Low lung collapse PEEP

    Other: Change in PEEP

  • Experimental
    Low lung overdistention PEEP

    Other: Change in PEEP

Interventions

  • OtherChange in PEEP

    Patients will undergo a decremental PEEP trial to determine the crossing-point PEEP. Secondly, three PEEP levels (low collapse PEEP, low overdistention PEEP and crossing point between lung collapse and overdistention PEEP) will be compared in a randomized order with 30-minute steps

06

What researchers measure

Primary outcomes

  1. Impact of lung collapse on cardiac output

    Evaluation of the relative contribution of lung collapse (arbitrary units) on patients' cardiac output at different PEEP levels (L/min)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  2. Impact of lung collapse on pulmonary vascular resistance

    Evaluation of the relative contribution of lung collapse (arbitrary units) on pulmonary vascular resistance (dyn·s/cm\^5) at different PEEP levels

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  3. Impact of lung overdistention on cardiac output

    Evaluation of the relative contribution of lung overdistention (arbitrary units) on patients' cardiac output at different PEEP levels (L/min)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  4. Impact of lung overdistention on pulmonary vascular resistance

    Evaluation of the relative contribution of lung overdistention (arbitrary units) on pulmonary vascular resistance (dyn·s/cm\^5) at different PEEP levels

    Time frame: Assesment performed at the end of each of the three 30 minute steps

Secondary outcomes

  1. Correlation between potential for lung recruitment and PEEP-induced changes in cardiac output

    The effects of PEEP on cardiac output (mL/min) will be correlated through Pearson correlations with the individual potential for lung recruitment, as determined by the recruitment-to-inflation ratio (R/I)

    Time frame: Assessment at the end of each of the three 30 minute steps

  2. Correlation between potential for lung recruitment and PEEP-induced changes in pulmonary vascular resistance

    The effects of PEEP on pulmonary vascular resistance (dyn·s/cm\^5) will be correlated through Pearson correlations with the individual potential for lung recruitment, as determined by the recruitment-to-inflation ratio (R/I)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  3. PEEP-induced effects on cardiac output in cardiac preload responsive vs. nonresponsive patients

    The effects of PEEP on cardiac output (L/min) will be compared through subgroup comparisons (student t-test) in patients who are preload responsive and patients who are not (preload responsiveness assessed through pulse-pressure variation, expressed in %)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  4. PEEP-induced effects on pulmonary vascular resistance in cardiac preload responsive vs. nonresponsive patients

    The effects of PEEP on pulmonary vascular resistance (dyn·s/cm\^5) will be compared through subgroup comparisons (student t-test) in patients who are preload responsive and patients who are not (preload resposnsiveness assessed through pulse-pressure variation, expressed in %)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  5. Relationship between transpulmonary pressures and central venous pressure variations

    The relationship between transpulmonary pressure variations (cmH2O) and central venous pressure variations (cmH2O) between PEEP levels will be assessed through Pearson correlations

    Time frame: At the end of each of the three 30 minute steps

  6. Lung hysteresis

    Lung hysteresis will be assessed at each of the tested PEEP levels and expressed as the area of the pressure-volume loop of the respiratory system obtained with a low-flow inflation/deflation maneuver from PEEP to a pressure of 30 cmH2O, in mL\*cmH2O

    Time frame: At the end of each of the three 30 minute steps

  7. Lung aeration distribution

    Lung aeration distribution at each PEEP level tested will be assessed with electrical impedance tomography (EIT) and expressed as dorsal fraction of ventilation (% of total tidal volume)

    Time frame: At the end of each of the three 30 minute steps

  8. Relationship between PEEP-induced changes in lung volume and PEEP-induced changes in pulmonary vascular resistance

    The effects of PEEP on pulmonary vascular resistance (dyn·s/cm\^5) will be correlated through Pearson correlations with the individual PEEP-induced changes in lung volume (mL)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

  9. Relationship between PEEP-induced changes in lung volume and PEEP-induced changes in cardiac output

    The effects of PEEP cardiac output (L/min) will be correlated through Pearson correlations with the individual PEEP-induced changes in lung volume (mL)

    Time frame: Assesment performed at the end of each of the three 30 minute steps

07

Study locations

1 site
  • Fondazione Policlinico Universitario A.Gemelli IRCCS
    Rome, Rome 00168, Italy
    • Domenico Luca Grieco, MD · Contactdlgrieco@outlook.it · +393397681623
    • Massimo Antonelli, MD · Principal investigator
    • Tommaso Rosà, MD · Sub investigator
    • Antonio Maria Dell'Anna, MD · Sub investigator
    • Simone Carelli, MD · Sub investigator
    • Filippo Bongiovanni, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07423520
Responsible party
GRIECO DOMENICO LUCA (Medical Doctor, Principal Investigator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Feb 20, 2026
Start date
Feb 28, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Domenico Luca Grieco, MD
Contact
dlgrieco@outlook.it
+393397681623
Domenico Luca Grieco, MD
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion